The Persistent Corneal Epithelial Defects drugs in development market research report provides comprehensive information on the therapeutics under development for Persistent Corneal Epithelial Defects, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Persistent Corneal Epithelial Defects. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Persistent Corneal Epithelial Defects and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Persistent Corneal Epithelial Defects by seven companies/universities/institutes. The top development phase for Persistent Corneal Epithelial Defects is preclinical with three drugs in that stage. The Persistent Corneal Epithelial Defects pipeline has seven drugs in development by companies and one by universities/ institutes. Some of the companies in the Persistent Corneal Epithelial Defects pipeline products market are: Dominion Minerals, Lee’s Pharmaceutical and Xequel Bio.
The key targets in the Persistent Corneal Epithelial Defects pipeline products market include Integrin Alpha V (Vitronectin Receptor Subunit Alpha or CD51 or ITGAV), Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3), and Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1).
The key mechanisms of action in the Persistent Corneal Epithelial Defects pipeline product include Actin Inhibitor with one drug in Phase II. The Persistent Corneal Epithelial Defects pipeline products include three routes of administration with the top ROA being Ophthalmic and seven key molecule types in the Persistent Corneal Epithelial Defects pipeline products market including Fusion Protein, and Cell Therapy.
Persistent Corneal Epithelial Defects overview
Persistent corneal epithelial defects result from failure of re-epithelialization and complete healing within two weeks of corneal epithelial insult, even after conventional treatment. Persistent epithelial defects necessitate prompt and vigilant treatment to avoid associated potential complications, such as infection, vision loss, corneal scarring, melting, and even perforation
For a complete picture of Persistent Corneal Epithelial Defects’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
